COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #205 of 237
12/9 Late treatment study
Guglielmetti et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.11.012 (Peer Reviewed)
Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave
Source   PDF   Share   Tweet
Retrospective 218 hospitalized patients in Italy showing non-statistically significant 35% lower mortality with HCQ, hazard ratio aHR 0.65 [0.33–1.30].

Guglielmetti et al., 12/9/2020, retrospective, Italy, Europe, peer-reviewed, 16 authors.
risk of death, 35.0% lower, RR 0.65, p = 0.22, treatment 181, control 37, adjusted per study, multivariable Cox.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.